Open Access

MicroRNA‑564 inhibits the progression of non‑small cell lung cancer via targeting plexin A4

  • Authors:
    • Hui Ding
    • Liangpeng Li
    • Biao Gu
    • Yaojun Ni
    • Sheng Chen
  • View Affiliations

  • Published online on: February 13, 2021     https://doi.org/10.3892/etm.2021.9789
  • Article Number: 358
  • Copyright: © Ding et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Νon‑small cell lung cancer (NSCLC) is the most frequently diagnosed type of cancer, and the most prevalent cause of cancer‑associated mortality. The present study aimed to investigate whether microRNA (miR)‑564 influences NSCLC progression by regulating NSCLC cell growth and migration, via targeting plexin A4. Therefore, the expression levels of miR‑564 and plexin A4 were evaluated in NSCLC specimens or cells using reverse transcription‑quantitative PCR. Furthermore, colony formation and Cell Counting Kit‑8 assays were performed to determine the proliferative ability of NSCLC cells. The cell migration capacity was assessed using a Transwell assay. In addition, to examine the binding ability of miR‑564 on the plexin A4 3'‑untranslated region (3'UTR), a dual‑luciferase reporter assay was performed. A mouse xenograft model was established to evaluate the effect of miR‑564 knockdown on tumor growth in vivo, whereas the expression of plexin A4 and Ki67 in NSCLC tissues was detected using immunohistochemistry. Notably, miR‑564 was downregulated in both NSCLC cell lines and tissues, while its overexpression, following transfection with miR‑564 mimics, attenuated the proliferation and proliferation, migration and invasion of NSCLC cells. By contrast, silencing of miR‑564 using a miR‑564 inhibitor promoted NSCLC cell proliferation, migration and invasion. The luciferase assay revealed that miR‑564 directly targeted the plexin A4 3'UTR in A549 and H460 cells. Additionally, the overexpression of plexin A4 rescued the effect of miR‑564 on NSCLC cell proliferation, migration and invasion abilities. Further in vivo studies demonstrated that miR‑564 knockdown promoted NSCLC growth, while miR‑564 overexpression resulted in the opposite effect in nude mice. Overall, the results of the present study revealed that miR‑564 promotes the proliferation and migration of NSCLC cells, both in vitro and in vivo, via targeting plexin A4. Therefore, miR‑564 may be considered as a possible therapeutic target for NSCLC.
View Figures
View References

Related Articles

Journal Cover

April-2021
Volume 21 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ding H, Li L, Gu B, Ni Y and Chen S: MicroRNA‑564 inhibits the progression of non‑small cell lung cancer via targeting plexin A4. Exp Ther Med 21: 358, 2021.
APA
Ding, H., Li, L., Gu, B., Ni, Y., & Chen, S. (2021). MicroRNA‑564 inhibits the progression of non‑small cell lung cancer via targeting plexin A4. Experimental and Therapeutic Medicine, 21, 358. https://doi.org/10.3892/etm.2021.9789
MLA
Ding, H., Li, L., Gu, B., Ni, Y., Chen, S."MicroRNA‑564 inhibits the progression of non‑small cell lung cancer via targeting plexin A4". Experimental and Therapeutic Medicine 21.4 (2021): 358.
Chicago
Ding, H., Li, L., Gu, B., Ni, Y., Chen, S."MicroRNA‑564 inhibits the progression of non‑small cell lung cancer via targeting plexin A4". Experimental and Therapeutic Medicine 21, no. 4 (2021): 358. https://doi.org/10.3892/etm.2021.9789